Multi-Scale Transcriptomic Sequencing Data Analysis Reveals LINC00467 is Associated with Malignant Progression in Breast Cancer: An In Silico and In Vitro Study.

OBJECTIVE

Long non-coding RNAs have been found to play a pivotal role in breast cancer, yet the majority of these lncRNAs remain to be thoroughly investigated. This study aimed to explore the role of differentially expressed long non-coding RNAs (lncRNAs) in breast cancer stemness and drug sensitivity.

METHODS

Database mining was performed to evaluate the expression of LINC00467 in different types of breast cancer and its association with clinical features. The function of LINC00467 was examined through colony formation assays, quantitative reverse transcription PCR (qRT-PCR), and western blotting following LINC00467 silencing in breast cancer cell lines.

RESULTS

LINC00467 was significantly upregulated in various breast cancer subtypes with spatial specificity. Silencing LINC00467 reduced clonogenic capacity and downregulated the stemness-associated factor LIN28B as well as phosphorylated RAC-alpha serine/threonine-protein kinase (p-AKT). The transcription factors specificity protein 1 (SP1) and E2F transcription factor 1 (E2F1) were predicted to bind to the LINC00467 promoter. Furthermore, breast cancer samples with high LINC00467 expression displayed reduced sensitivity to AKT inhibitors, and high LINC00467 expression was negatively correlated with the therapeutic response to programmed cell death 1 (PD-1) antibodies.

CONCLUSION

Our findings suggest that spatially expressed LINC00467 may promote breast cancer stemness by regulating AKT signaling and could serve as a potential new therapeutic target and indicator of drug sensitivity in breast cancer.